Decoy receptor 2 (DcR2) is a p53 target gene and regulates chemosensitivity.

Decoy receptor 2 (DcR2) is one of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptors and suppresses TRAIL-induced apoptosis. Its expression, like the other three TRAIL receptors (i.e., DR4, DR5, and DcR1), is regulated by p53. Here, we report that DcR2 is a p53 target gene and regulates chemosensitivity. In this study, we identified a p53-binding site (p53BS) in the first intron of the DcR2 gene. This p53BS is almost identical to the ones found in the first introns of other three TRAIL receptor genes. By a chromatin immunoprecipitation assay, we detected that the p53 protein bound to the DcR2 p53BS in intact cells. Subcloning of the DcR2 p53BS into a luciferase reporter vector driven by a SV40 promoter exhibited enhanced luciferase activity when transiently cotransfected with a wild-type (wt) p53 expression vector in p53-null cell lines or stimulated with DNA-damaging agents in cell lines having wt p53. Moreover, when the DcR2 p53BS, together with its own corresponding promoter regions, was subcloned into a basic luciferase vector without a promoter element, its transcriptional activities were strikingly increased by cotransfection of the wt p53 gene. However, when this p53BS was deleted from the construct, wt p53 failed to transactivate this reporter construct. Collectively, we conclude that p53 directly regulates the DcR2 gene expression via an intronic p53BS. In addition, overexpression of DcR2 conferred resistance to TRAIL-mediated apoptosis and attenuated cell response to DNA-damaging agents, whereas silencing of DcR2 expression enhanced chemotherapeutic agent-induced apoptosis. These results suggest that DcR2 regulates chemosensitivity.

[1]  A. Evdokiou,et al.  Death to the bad guys: Targeting cancer via Apo2L/TRAIL , 2005, Apoptosis.

[2]  F. Khuri,et al.  Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells. , 2004, Journal of the National Cancer Institute.

[3]  F. Khuri,et al.  p53 Upregulates Death Receptor 4 Expression through an Intronic p53 Binding Site , 2004, Cancer Research.

[4]  S. Toyooka,et al.  Aberrant methylation of trail decoy receptor genes is frequent in multiple tumor types , 2004, International journal of cancer.

[5]  J. Redondo,et al.  Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) Decoy Receptor TRAIL-R3 Is Up-regulated by p53 in Breast Tumor Cells through a Mechanism Involving an Intronic p53-binding Site* , 2004, Journal of Biological Chemistry.

[6]  M. Oren,et al.  Decision making by p53: life, death and cancer , 2003, Cell Death and Differentiation.

[7]  J. Manfredi,et al.  p53 and apoptosis: it's not just in the nucleus anymore. , 2003, Molecular cell.

[8]  Xin Lu,et al.  Live or let die: the cell's response to p53 , 2002, Nature Reviews Cancer.

[9]  J. Herman,et al.  Tumor-specific down-regulation of the tumor necrosis factor-related apoptosis-inducing ligand decoy receptors DcR1 and DcR2 is associated with dense promoter hypermethylation. , 2002, Cancer research.

[10]  W. el-Deiry,et al.  Insights into cancer therapeutic design based on p53 and TRAIL receptor signaling , 2001, Cell Death and Differentiation.

[11]  S. Benchimol p53-dependent pathways of apoptosis , 2001, Cell Death and Differentiation.

[12]  Sam W. Lee,et al.  p53 induction of heparin‐binding EGF‐like growth factor counteracts p53 growth suppression through activation of MAPK and PI3K/Akt signaling cascades , 2001, The EMBO journal.

[13]  A. Levine,et al.  Surfing the p53 network , 2000, Nature.

[14]  A. Fornace,et al.  Death and decoy receptors and p53-mediated apoptosis , 2000, Leukemia.

[15]  W. El-Deiry,et al.  Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site , 2000, Oncogene.

[16]  A. Fornace,et al.  The TRAIL decoy receptor TRUNDD (DcR2, TRAIL-R4) is induced by adenovirus-p53 overexpression and can delay TRAIL-, p53-, and KILLER/DR5-dependent colon cancer apoptosis. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

[17]  J. Levine,et al.  Surfing the p53 network , 2000, Nature.

[18]  H. Friess,et al.  The antiapoptotic decoy receptor TRID/TRAIL-R3 is a p53-regulated DNA damage-inducible gene that is overexpressed in primary tumors of the gastrointestinal tract , 1999, Oncogene.

[19]  R. Lotan,et al.  Mechanisms of apoptosis induced by the synthetic retinoid CD437 in human non-small cell lung carcinoma cells , 1999, Oncogene.

[20]  V. Dixit,et al.  Death receptors: signaling and modulation. , 1998, Science.

[21]  V. Dixit,et al.  TRUNDD, a new member of the TRAIL receptor family that antagonizes TRAIL signalling , 1998, FEBS letters.

[22]  C. Smith,et al.  The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. , 1997, Immunity.

[23]  A. Gurney,et al.  A novel receptor for Apo2L/TRAIL contains a truncated death domain , 1997, Current Biology.

[24]  R. Lotan,et al.  Differential effects of synthetic nuclear retinoid receptor-selective retinoids on the growth of human non-small cell lung carcinoma cells. , 1997, Cancer research.

[25]  A. Levine p53, the Cellular Gatekeeper for Growth and Division , 1997, Cell.

[26]  I. Krantz,et al.  KILLER/DR5 is a DNA damage–inducible p53–regulated death receptor gene , 1997, Nature Genetics.

[27]  K. Kinzler,et al.  Definition of a consensus binding site for p53 , 1992, Nature Genetics.